These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 19066994)

  • 1. In-silico screening of new potential Bcl-2/Bcl-xl inhibitors as apoptosis modulators.
    Almerico AM; Tutone M; Lauria A
    J Mol Model; 2009 Apr; 15(4):349-55. PubMed ID: 19066994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the BH3 domain mediated protein-protein interaction of Bcl-xL through virtual screening.
    Mukherjee P; Desai P; Zhou YD; Avery M
    J Chem Inf Model; 2010 May; 50(5):906-23. PubMed ID: 20392095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based discovery of a new class of Bcl-xL antagonists.
    Rega MF; Leone M; Jung D; Cotton NJ; Stebbins JL; Pellecchia M
    Bioorg Chem; 2007 Aug; 35(4):344-53. PubMed ID: 17512966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3D-QSAR pharmacophore modeling and in silico screening of new Bcl-xl inhibitors.
    Almerico AM; Tutone M; Lauria A
    Eur J Med Chem; 2010 Nov; 45(11):4774-82. PubMed ID: 20728251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins.
    Tang G; Yang CY; Nikolovska-Coleska Z; Guo J; Qiu S; Wang R; Gao W; Wang G; Stuckey J; Krajewski K; Jiang S; Roller PP; Wang S
    J Med Chem; 2007 Apr; 50(8):1723-6. PubMed ID: 17378545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of PROTAC BCL-X
    Zhang X; Thummuri D; Liu X; Hu W; Zhang P; Khan S; Yuan Y; Zhou D; Zheng G
    Eur J Med Chem; 2020 Apr; 192():112186. PubMed ID: 32145645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines.
    Nuessler V; Stötzer O; Gullis E; Pelka-Fleischer R; Pogrebniak A; Gieseler F; Wilmanns W
    Leukemia; 1999 Nov; 13(11):1864-72. PubMed ID: 10557064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
    Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
    Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y; Harashima N; Tajima Y; Harada M
    Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of 3-phenyl-N-(2-(3-phenylureido)ethyl)-thiophene-2-sulfonamide compounds as inhibitors of antiapoptotic Bcl-2 family proteins.
    Yang C; Chen S; Zhou M; Li Y; Li Y; Zhang Z; Liu Z; Ba Q; Li J; Wang H; Yan X; Ma D; Wang R
    ChemMedChem; 2014 Jul; 9(7):1436-52. PubMed ID: 24782462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening.
    Enyedy IJ; Ling Y; Nacro K; Tomita Y; Wu X; Cao Y; Guo R; Li B; Zhu X; Huang Y; Long YQ; Roller PP; Yang D; Wang S
    J Med Chem; 2001 Dec; 44(25):4313-24. PubMed ID: 11728179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of functional groups in predicting the activity of small molecule inhibitors for Bcl-2 and Bcl-xL.
    Kanakaveti V; Sakthivel R; Rayala SK; Gromiha MM
    Chem Biol Drug Des; 2017 Aug; 90(2):308-316. PubMed ID: 28112863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homology Modeling and Docking Studies of Bcl-2 and Bcl-xL with Small Molecule Inhibitors: Identification and Functional Studies.
    Salam AAA; Nayek U; Sunil D
    Curr Top Med Chem; 2018; 18(31):2633-2663. PubMed ID: 30659540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer.
    Stover EH; Baco MB; Cohen O; Li YY; Christie EL; Bagul M; Goodale A; Lee Y; Pantel S; Rees MG; Wei G; Presser AG; Gelbard MK; Zhang W; Zervantonakis IK; Bhola PD; Ryan J; Guerriero JL; Montero J; Liang FJ; Cherniack AD; Piccioni F; Matulonis UA; Bowtell DDL; Sarosiek KA; Letai A; Garraway LA; Johannessen CM; Meyerson M
    Mol Cancer Res; 2019 Nov; 17(11):2281-2293. PubMed ID: 31462500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcl-2 family proteins as targets for anticancer drug design.
    Huang Z
    Oncogene; 2000 Dec; 19(56):6627-31. PubMed ID: 11426648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of inhibitors of Bcl-2 family protein-protein interaction by combining the BRET screening platform with virtual screening.
    Park IS; Seo HR; Kim K; Lee H; Shum D; Choi I; Kim J
    Biochem Biophys Res Commun; 2020 Jun; 527(3):709-715. PubMed ID: 32423828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade.
    Williams MM; Lee L; Hicks DJ; Joly MM; Elion D; Rahman B; McKernan C; Sanchez V; Balko JM; Stricker T; Estrada MV; Cook RS
    Mol Cancer Res; 2017 Mar; 15(3):259-268. PubMed ID: 28039357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An inhibitor of Bcl-2 family proteins induces regression of solid tumours.
    Oltersdorf T; Elmore SW; Shoemaker AR; Armstrong RC; Augeri DJ; Belli BA; Bruncko M; Deckwerth TL; Dinges J; Hajduk PJ; Joseph MK; Kitada S; Korsmeyer SJ; Kunzer AR; Letai A; Li C; Mitten MJ; Nettesheim DG; Ng S; Nimmer PM; O'Connor JM; Oleksijew A; Petros AM; Reed JC; Shen W; Tahir SK; Thompson CB; Tomaselli KJ; Wang B; Wendt MD; Zhang H; Fesik SW; Rosenberg SH
    Nature; 2005 Jun; 435(7042):677-81. PubMed ID: 15902208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemosensitization of solid tumors by inhibition of Bcl-xL expression using DNAzyme.
    Yu X; Yang L; Cairns MJ; Dass C; Saravolac E; Li X; Sun LQ
    Oncotarget; 2014 Oct; 5(19):9039-48. PubMed ID: 25344863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer.
    Doshi JM; Tian D; Xing C
    J Med Chem; 2006 Dec; 49(26):7731-9. PubMed ID: 17181155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.